Life-time estrogen exposure and cognitive functioning in later life.
Joanne Ryan, Isabelle Carrière, Jacqueline Scali, Karen Ritchie, Marie-Laure Ancelin

To cite this version:
TABLE 1. Baseline characteristics of the 996 participants.

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥12 years of education</td>
<td>28.6</td>
</tr>
<tr>
<td>Married or has a Partner</td>
<td>53.9</td>
</tr>
<tr>
<td>High Alcohol Intake (≥24 grams per day)</td>
<td>6.0</td>
</tr>
<tr>
<td>High Caffeine Intake (equivalent to ≥3 cups of coffee per day)</td>
<td>35.9</td>
</tr>
<tr>
<td>Current Smoker (≥10plts each year)</td>
<td>3.7</td>
</tr>
<tr>
<td>Carrier of the Apoe4 allele</td>
<td>17.8</td>
</tr>
<tr>
<td>Depression (CESD≥16)</td>
<td>34.5</td>
</tr>
<tr>
<td>Anticholinergic Medication</td>
<td>6.3</td>
</tr>
<tr>
<td>Antidepressant or Benzodiazepine Medication</td>
<td>9.6</td>
</tr>
<tr>
<td>Comorbidity *</td>
<td>37.7</td>
</tr>
<tr>
<td>Incapacities</td>
<td>4.2</td>
</tr>
</tbody>
</table>

**Mean (sd)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>72.8 (5.5)</td>
</tr>
<tr>
<td>Age at 1st Menses</td>
<td>13.1 (1.6)</td>
</tr>
<tr>
<td>Age at Menopause</td>
<td>49.5 (5.4)</td>
</tr>
<tr>
<td>Number of Reproductive Years</td>
<td>36.6 (5.6)</td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical Menopause</td>
<td>18.7</td>
</tr>
<tr>
<td>Oral Contraceptive Use</td>
<td>19.1</td>
</tr>
<tr>
<td>Nulliparous</td>
<td>12.0</td>
</tr>
</tbody>
</table>

**Number of Children**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>12.0</td>
</tr>
<tr>
<td>1</td>
<td>16.3</td>
</tr>
<tr>
<td>2 or 3</td>
<td>54.8</td>
</tr>
<tr>
<td>&gt;3</td>
<td>16.9</td>
</tr>
</tbody>
</table>

**Age at birth of 1st child**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 20</td>
<td>18.7</td>
</tr>
<tr>
<td>21 - 29</td>
<td>59.4</td>
</tr>
<tr>
<td>≥ 30</td>
<td>21.9</td>
</tr>
</tbody>
</table>

**Hormone Treatment (HT)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Never</td>
<td>65.8</td>
</tr>
<tr>
<td>Past</td>
<td>19.4</td>
</tr>
<tr>
<td>Current</td>
<td>14.8</td>
</tr>
</tbody>
</table>

**Duration of HT**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Never</td>
<td>65.8</td>
</tr>
<tr>
<td>0 – 9 years of Past use</td>
<td>11.8</td>
</tr>
<tr>
<td>≥ 10 years of Past use</td>
<td>7.6</td>
</tr>
<tr>
<td>0 – 9 years of Current use</td>
<td>3.7</td>
</tr>
<tr>
<td>≥ 10 years of Current use</td>
<td>11.0</td>
</tr>
</tbody>
</table>

*a* includes a chronic disease (cardiovascular disease, other heart problems, high blood pressure, high cholesterol, diabetes, thyroid problems), or cancer diagnosed within the last 2 years. *c* Age at menopause minus age at first menses. *b* N=876 parous women.